

PGx in Cardiology — Antiplatelets, Statins & Warfarin — Hands-on

Connect pharmacogenomics with day to day cardiology decisions. This module focuses on antiplatelets, statins and warfarin, helping you interpret relevant gene-drug pairs, anticipate thrombosis, myopathy and bleeding risk, and write clear, cardiology focused PGx recommendations.

PGx in Cardiology — Antiplatelets Statins and Warfarin

[Help Desk · WhatsApp](#)

Session Index

[Session 1 — Cardiology PGx Foundations & Pathways](#) [Session 2 — Antiplatelets, Thrombosis Risk & PGx](#) [Session 3 — Statins, Myopathy Risk & PGx](#) [Session 4 — Warfarin, Anticoagulation & PGx](#)
[Caseboard](#)

Session 1

Fee: Rs 8800 [Apply Now](#)

Cardiology PGx Foundations & Pathways

Where pharmacogenomics fits in cardiology practice

[ACS and PCI workflows](#) [stroke and AFib prevention](#)
[lipid management and risk scores](#)

Key ADME pathways for cardiology drugs

[phase 1 and phase 2 metabolism](#) [hepatic vs renal clearance](#)
[transporters and uptake](#)

Risk outcomes: thrombosis, bleeding and myopathy overview

stent thrombosis and stroke **major bleeding events**
CK elevation and rhabdomyolysis

Session 2

Fee: Rs 11800 Apply Now

Antiplatelets, Thrombosis Risk & PGx

Concepts around antiplatelet response variability

prodrugs vs active drugs **on treatment platelet reactivity** **high on treatment platelet reactivity**

Gene–drug concepts for antiplatelets (CYP metabolism)

reduced function vs normal activity **effect on active metabolite formation** **thrombosis vs bleeding trade offs**

Antiplatelet choice and dose themes in PGx guidelines

when to consider alternative agents **balancing ischemic and bleeding risks** **multidisciplinary decision making**

Session 3

Fee: Rs 14800 Apply Now

Statins, Myopathy Risk & PGx

Mechanisms of statin induced myopathy (conceptual)

exposure driven risk **drug–drug interactions** **patient susceptibility factors**

Transporter related concepts for statin uptake and exposure

hepatic uptake transporters **higher systemic concentrations** **myopathy signal recognition**

Statin selection, dosing and follow up themes in PGx

starting and target doses **panel vs single gene**
considerations **CK monitoring and symptom review**

Session 4

Fee: Rs 18800 Apply Now

Warfarin, Anticoagulation & PGx Caseboard

Warfarin dosing variability and PGx concepts

sensitivity vs resistance themes **maintenance dose**
prediction intuition **INR trajectories and safety**

Clinical factors plus PGx in anticoagulation decisions

age, comorbidities, interactions **bridging and overlap**
periods **role of DOAC options**

Mini capstone: cardiology PGx clinic note and board slide

summarize antiplatelet, statin and anticoagulant PGx
clear risk and action bullets **ready for cardiology**
case discussions